Making the Connection

 Between Patients and Providers

A Modern Approach to the Treatment of Type 1 and Type 2 Diabetes



An engaging & entertaining

For Savvy Healthcare Professionals


…five distinct areas of the most cutting-edge diabetes management strategies:

  • Clinical trials and why positive results disappear in real-world practice
  • The emotional barriers that affect diabetes management and how to work through them
  • Oral medications for the treatment of type 2 diabetes
  • Injectable agents including GLP-1 receptor agonists, basal insulin and more intensive regimens
  • State-of-the-art treatment strategies for people with type 1 diabetes


Meet TCOYD’s Founder & Director

Dr. Steven V. Edelman is a Clinical Professor of Medicine at UCSD School of Medicine, the Director of the Diabetes Care Clinic at the VA Medical Center in San Diego and a type 1 since the age of 15. He’s dedicated his medical career to bringing diabetes education and cutting-edge management strategies directly to the people who need it most, people who have diabetes and the medical professionals who treat them.

“Thank you for continuing to provide this excellent educational event for health professionals who treat people with diabetes. This conference should be made mandatory for all primary care providers!”

– Santa Clara, CA Making the Connection Conference Participant

…in addition a mix of rotating key opinion leaders bringing exciting & engaging education to seeking professionals.

  • William Polonsky, PhD, CDE – President, Behavioral Diabetes Institute; Associate Clinical Professor, Department of Psychiatry, University of California San Diego
  • Ian Blumer, MD, FRCPC – Charles H. Best Diabetes Centre, University of Toronto
  • James R. Gavin III, MD, PhD – Clinical Professor of Medicine, Emory University School of Medicine
  • Maury Gloster, MD – Founder of the Sutter Diabetes Care Center; Medical Consultant, Medical Board of California, Sacramento, CA
  • Tricia Santos Cavaiola, MD – University of California, San Diego School of Medicine
  • Juan P. Frias, MD – President, National Research Institute; Clinical Faculty, Department of Medicine, University of California, San Diego
  • Robert R. Henry, MD – Director, Center for Metabolic Research; Chief, Section of Diabetes, Endocrinology and Metabolism, San Diego VA Healthcare System; Professor of Medicine, University of California, San Diego
  • J. Ross Tanner, DO, FACP – Internal Medicine and Clinical Lipidology, Diabetes and Lipid Clinic of Alaska
  • Melissa Magwire, RN, CDE – Endocrine Clinic Supervisor; Shawnee Mission Endocrinology and Diabetes, Kansas


Savvy healthcare professionals who attend Making the Connection will…

  • LEARN from the nations LEADING experts in diabetes treatment
  • Earn 6.25 CME CREDITS
  • Enjoy a healthy & delicious BREAKFAST & LUNCH
  • Recieve DOWNLOADABLE slide decks of all speaker presentations
  • Most importantly, help THEIR PATIENTS reach their treatment goals


Attend a TCOYD Making the Connection Conference Near You!


Feb. 3, 2018

Anchorage, AK

William A. Egan Civic & Convention Center

March 3, 2018

Sacramento, CA

Sacramento Convention Center Complex

March 17, 2018

Monterey, CA

Monterey Conference Center

April 7, 2018

Novi, MI

Suburban Collective Showplace

May 5, 2018

Honolulu, HI

Hawaii Convention Center

June 2, 2018

Spokane, WA

Spokane Convention Center

Sept. 8, 2018

Nashville, TN

Music City Center

Nov. 17, 2018

San Diego, CA

San Diego Convention Center


Learning Objectives

At course completion, participants should be able to:

1. Discuss the different pathophysiologic defects associated with type 2 diabetes and how all of the pharmacologic agents (oral and injectable) address these specific abnormalities.6. Design an easy-to-implement treatment plan for initiation of pump therapy and subsequent adjustments based on home and/or continuous glucose monitoring data.
2. Summarize the recently published cardiovascular outcome trials (CVOTs) on oral and injectable type 2 medications and be able to discuss their implications in terms of clinical application.7. Discuss the information that continuous glucose monitoring technology provides and describe effective therapeutic adjustments based on trending or rate of change arrows.
3. Discuss approaches to combination therapy with the currently available oral agents including metformin, TZDs, an SFUs, SGLT-2 inhibitors, DPP4 inhibitors as well as GLP-1 receptor agonists.8. Evaluate the physical and emotional barriers that prevent patients with diabetes from being persistent and adherent to their therapeutic regimen(s) thus preventing achievement of metabolic control.
4. Discuss physician and patient-directed insulin titration strategies used in clinical practice for combination therapy and basal bolus approach.9. Employ innovative and dynamic strategies for communication with patients to strengthen provider-patient relations and improve patient outcomes.
5. Outline the most up-to-date clinical information on GLP-1 receptor agonists and SGLT-2 inhibitors, including prescribing guidelines and safety issues.


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Uni­versity of California, San Diego School of Medicine and Taking Control of Your Diabetes. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

AMA: The University of California, San Diego School of Medicine designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: For the purposes of recertification, the American Nurses Credentialing Center accepts AMA PRA Cate­gory 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the Califor­nia Board of Registered Nursing accepts AMA PRA Category 1 credits™ (report up to 6.25 hours of credit and list “CME Category 1” as the provider number).

Physician Assistants: The AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Phy­sician assistants may receive a maximum of 6.25 hours of Category 1 credit for completing this program.

Pharmacists: The California Board of Pharmacy accepts as continuing education for pharmacist’s coursework which meets the standard of relevance to pharmacy practice and is accepted as continuing education by the Medical Board of California.

Certified Diabetes Educators: The University of California, San Diego is accredited by the ACCME, which is on the NCBDE list of approved providers.

Dieticians: AMA PRA Category 1 Credits™ meet the requirements of the Commission on Dietetic Registration (CDR).

Cultural and Linguistic Competency

This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient’s primary language. Cultural and linguistic competency was incorporated into the planning of this activity. Additional resources can be found on the UC San Diego CME website.


Did you recently attend the Making the Connection program?

Click to claim your much deserved CME credits! Hope you enjoyed the conference!

Acknowledgement of Commercial Support

This activity is supported by educational grants from:

Abbott Diabetes Care Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Insulet Corporation, Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Lilly USA LLC, MannKind Corporation